Departamento de Química Orgánica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113 Buenos Aires, Argentina.
Eur J Med Chem. 2011 Sep;46(9):3696-703. doi: 10.1016/j.ejmech.2011.05.035. Epub 2011 May 20.
Research and development of new drugs effective in the treatment of Trypanosoma cruzi infections are a real need for the 16 million people infected in the Americas. In a previous work, a quinoline derivative substituted by a 2-piperidylmethyl moiety showed to be active against Chagas disease and was considered a lead compound for further optimization. A series of ten analogous derivatives were tested against epimastigotes as a first approach. In view of their promising results, six of them were evaluated against the blood and intracellular replicative forms of the parasite in humans. Among them, compound 12 which possesses a 6-acetamidohexylamino substituent showed remarkable improvement in activity against epimastigotes, trypomastigotes and amastigotes compared with the structure lead, as well as a good selectivity index for the two parasite stages present in humans. In addition, treatment of infected mice with compound 12 induced a significant reduction in parasitemia compared with non-treated mice. Molecular modeling studies were performed by computational methods in order to elucidate the factors determining these experimental bioactivities.
治疗克氏锥虫感染的有效新药的研发是美洲 1600 万感染者的真正需求。在之前的一项工作中,一种被 2-哌啶甲基取代的喹啉衍生物对恰加斯病表现出活性,被认为是进一步优化的先导化合物。一系列十个类似的衍生物被测试对抗前鞭毛体作为初步方法。鉴于它们有希望的结果,其中 6 种被评估对人类寄生虫的血液和细胞内复制形式。其中,具有 6-乙酰氨基己基氨基取代基的化合物 12 与结构先导化合物相比,在前鞭毛体、锥鞭毛体和无鞭毛体中的活性显著提高,并且对人类中存在的两种寄生虫阶段具有良好的选择性指数。此外,用化合物 12 治疗感染的小鼠可显著降低寄生虫血症,与未治疗的小鼠相比。通过计算方法进行了分子建模研究,以阐明决定这些实验生物活性的因素。